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ABSTRACT 
Purpose – NGF and BDNF play a key role in OAB. Their high urinary levels in OAB 
patients subsided after successful antimuscarinic treatment. In this study, we 
investigated, for the first time, urinary NGF and BDNF levels after mirabegron 
treatment, a β3-adrenoceptor agonist recently approved to treat this disease.  
 
Materials and Methods – Twenty-two female OAB patients were enrolled. If they were 
taken antimuscarinics and not satisfied, a washout period of 4 weeks was required. As 
control, fifteen women without LUTS were used. At baseline, urine samples were 
collected from all participants and KHQ and PPBC questionnaires were completed. 
OAB patients were treated with mirabegron 50mg, once daily, and reevaluated at 4 and 
12 weeks. At these time points, urine sampling and completion of the same 
questionnaires were carried out. Urine samples were processed for ELISA analysis of 
NGF and BDNF and the values were normalized against creatinine concentration. 
Neurotrophins’ concentration values were logarithmized to improve distribution 
characteristics.  
Results – At baseline, urinary NGF/Cr and BDNF/Cr were significantly higher in OAB 
patients compared to controls (NGF/Cr: 3.3±0.6 vs. 2.4±0.5, p<0.01; BDNF/Cr: 2.9±0.5 
vs. 2.6±0.4, p=0.028). After taken mirabegron, NGF/Cr and BDNF/Cr values fell but 
without statistical significance. Eighteen participants reported marked symptomatic 
improvement, according to KHQ and PPBC scores. 
Conclusions – Mirabegron does not change urinary neurotrophins’ levels in OAB 
patients, despite symptomatic improvement. Since mirabegron acts on bladder smooth 
muscle, with a reduced effect on the urothelium, which is believed to release most of 
urinary neurotrophins, it could be a possible explanation.  
 
 
 
Keywords 
Overactive bladder syndrome, mirabegron, neurotrophins, nerve growth factor, brain-
derived neurotrophic factor 
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INTRODUCTION 
Overactive bladder (OAB) is a symptom complex defined by the International 
Continence Society (ICS) as the presence of urgency, with or without urgency urinary 
incontinence (UUI), usually associated with frequency and nocturia, in the absence of 
proven infection or other obvious pathology.1 
With the continuous rise of life expectancy and consequent increase of the 
ageing population, OAB has reached an overall prevalence of 12%,2 a number which 
may rise to 40% in the population aged more than 75 years old.3 In addition, as a 
chronic, recurrent and progressive condition,4 OAB greatly impairs quality of life and 
entails substantial economical and social costs.5, 6 
The underlying pathophysiology of OAB remains elusive.7, 8 Among the different 
mechanisms that have been forwaded, the sensitization of bladder primary afferents, 
leading to an excess of bladder sensory input in the central nervous system, as gained 
progressive interest.8 As a consequence, neurotrophins, potent trophic factors, have 
been implicated in the emergence of OAB symptoms perhaps by changing the 
threshold of bladder sensory neurons and modulating their synaptic connections at the 
spinal cord level.9 Nerve growth factor (NGF) and brain-derived neurotrophic factor 
(BDNF) constitute the most well-studied neurotrophins in lower urinary tract (LUT). 
Both neurotrophins10, 11 are synthesized in the bladder, by urothelial and smooth 
muscle cells. This led to the investigation of urinary levels of NGF and BDNF in OAB 
patients.12 Up till now, several authors have reported high urinary levels of NGF13, 14 
and BDNF14, 15 in OAB patients that decreased following successful symptomatic 
treatment with either antimuscarinics14, 16 or onabotulinum toxin A treatment.17  
Recently, mirabegron, the first selective 3-adrenoceptor agonist, was approved 
by Japanese, American and European authorities for OAB treatment.18 It is the leading 
agent of a novel class of oral drugs for OAB with a distinct mechanism of action. 
Mirabegron causes detrusor relaxation during the storage phase of the micturition cycle 
by activation of adenylyl cyclase, with the subsequent formation of cyclic adenosine 
monophosphate (cAMP).19 To our knowledge, there are no studies addressing the 
effect of mirabegron on urinary levels of neurotrophins in OAB patients. Herewith, we 
intended to investigate this issue. 
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MATERIALS AND METHODS 
The local ethics committee approved the study. Informed consent was obtained 
from all participants. Twenty-two female OAB patients with symptoms for at least 3 
months were enrolled. Those medicated with antimuscarinics, but not satisfied with the 
treatment, completed a washout period of 4 weeks. An age-matched group of fifteen 
women without LUTS, including hospital and faculty employees and their relatives, 
were used as controls. 
OAB followed the ICS clinical definition as a symptom complex marked by 
urgency, with or without urgency incontinence, usually with frequency and nocturia, in 
the absence of an underlying metabolic or pathologic condition.1 Evaluation included 
anamnesis, physical examination, urinalysis, urine culture and cytology and bladder 
and renal ultrasound. Exclusion criteria were age less than 18 years, pregnancy, 
neurological disease, stress urinary incontinence, active UTI within 3 months, recurrent 
UTI, any systemic infectious or inflammatory condition, bladder outlet obstruction, 
significant pelvic organ prolapse, previous bladder or urethral surgery, urothelial 
neoplasms, previous pelvic radiotherapy, hematuria, urolithiasis and treatment with 
intravesical onabotulinum toxin A in the last 18 months. 
At baseline, urine samples were collected from all participants and King’s 
Health Questionnaire (KHQ)20 and Patient Perception of Bladder Condition (PPBC) 
questionnaire21 were completed. A higher score in KHQ indicates lower health-related 
quality of life and a higher PPBC score denotes more severe bladder problems. 
OAB patients were treated with mirabegron 50mg, once daily, for three months, 
if it was well tolerated. During this period, the drug was provided by the local pharmacy 
without economical expenses for the patients. The following evaluations were 
performed after 4 and 12 weeks. At these time points, urine sampling and completion 
of the same questionnaires were carried out.  
Urine collection was made in the outpatient clinic and samples were stored on 
an ice container at 4ºC for less than 2 hours. Afterwards, they were centrifuged at 
3,000 rpm for 10 minutes. Supernatant was collected in 1ml aliquots and the remainder 
was used to determine the creatinine concentration. Aliquots were frozen at -80ºC until 
further processing. Samples were thawed and processed for enzyme-linked 
immunosorbent assay (ELISA) analysis of NGF and BDNF concentrations with the 
Emax® ImmunoAssay System (Promega, USA), following the manufacturer 
instructions.  The amount of NGF/BDNF in the sample is measured at 450nm with a 
Synergy HT Microplate Reader (BioTek Instruments, USA). All samples were run in 
duplicate and values were averaged against a standard curve generated with known 
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amounts of NGF/BDNF. The urine NGF and BDNF content was normalized to 
creatinine (Cr) concentration (NGF/Cr and BDNF/Cr ratio – pg/mg). Neurotrophins’ 
concentration values were logarithmized to improve distribution characteristics.  
Data were expressed as the mean ± standard deviation (SD). The Mann-
Whitney U test and Wilcoxon signed-rank test were used for statistical analysis 
between groups when considering nonparametric data, while paired samples t-test was 
used for analysis of parametric data. Statistical significance was considered at p<0.05. 
 
 
RESULTS 
In the group of OAB patients, the mean age was 62 14 years, while in control 
group was 41  12 years. At baseline, urinary NGF/Cr and BDNF/Cr were significantly 
higher in OAB patients compared to healthy controls (table 1). During follow-up, two 
patients were excluded due to UTI, one at 4 weeks and the other at 12 weeks. 
After treatment with mirabegron, there was a slight decrease in mean urinary 
NGF/Cr and BDNF/Cr ratios, which however did not reach statistical significance 
(p>0.05) (Figure 1). Eighteen out of twenty-two patients reported marked symptomatic 
improvement, reflected in the variations of KHQ and PPBC scores. It is important to 
notice that a higher score in KHQ indicates lower health-related quality of life and a 
higher PPBC score denotes more severe bladder problems. Data are summarized in 
table 2. 
 
 
DISCUSSION 
This is the first study investigating NGF and BDNF changes in the urine of OAB 
patients treated with mirabegron, the first 3-adrenoceptor agonist to enter clinical 
practice. 
According to our findings, OAB symptoms are associated with high urinary 
levels of NGF and BDNF. Mirabegron does not significantly change urinary levels of 
both neurotrophins, despite causing marked symptomatic improvement. These results 
are in contrast with previously published observations carried out with 
antimuscarinics14, 16 and onabotulinum toxin A treatment.17 
In the bladder, muscarinic receptors M2 and M3 can be found in the urothelium, 
interstitial cells, afferent nerves and detrusor muscle.22 In smooth muscle cells, the 
activation of these receptors involve different intracellular pathways and determine 
opposed effects. M1, M3, and M5 receptors are excitatory whereas M2 and M4 
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receptors are inhibitory. Although the M2 receptors predominate in the detrusor, the M3 
receptors mediate the central part of the contraction.23 Muscarinic receptors are 
functionally coupled to G proteins but the signal transduction systems vary. The M3 
receptor-mediated contractile response in the bladder depends on intracellular calcium 
increase through activation of phospholipase C, nifedipine-sensitive channels and the 
Rho-kinase pathway.22 Contrariwise, the functional role of M2 receptor is still not well 
clarified. They may enhance contractions mainly by inhibition of detrusor relaxation. M2 
stimulation may reduce adenylyl cyclase activity, inhibit potassium channels and affect 
nonselective cation and transient receptor potential channels.23 
In addition, it has been proposed that another mechanism underlying 
antimuscarinics effects in the treatment of OAB symptoms is the inhibition of afferent 
signaling from the bladder.24, 25 Taking into account that both urothelial and detrusor 
smooth muscle cells express muscarinic receptors and are able to synthesize and 
release neurotrophins,26 it is conceivable that antimuscarinics may hamper 
neurotrophins secretion, increasing the threshold of bladder sensory fibers16 and 
causing the reduction of urgency episodes. In this particular, it should be noted that 
detrusor cells are situated deep within the bladder wall. Therefore, neurotrophins 
released by the muscle have smaller chance of reaching the bladder lumen than 
neurotrophins released from urothelial cells, as they would have to cross the entire 
lamina propria and urothelium before reaching the bladder cavity.26 This means that the 
most probable source of urinary neurotrophins, which we can see decreasing in the 
urine of OAB patients after satisfactory antimuscarinic treatment,14, 16 is thought to be 
the urothelium.  
As an agonist of β3-adrenoceptor, it has been proposed that mirabegron 
induces bladder relaxation by increasing adenylyl cyclase, and subsequently cAMP, in 
detrusor smooth muscle cells, during urine storage. In addition, recent studies suggest 
that, in the bladder, potassium channels, and particularly big potassium (BK) channels, 
may be involved in β-adrenoceptor-mediated relaxation independently of cAMP.27  
Although β3-adrenoceptors are known to be abundant in the detrusor smooth 
muscle cells, little is known about its expression in human urothelial cells. Some 
authors have demonstrated the presence of β3-adrenoceptors in urothelial cells, using 
RT-PCR and immunohistochemistry techniques.28, 29 However, up to now, the 
functional role of 3-adrenoceptor in human urothelium, cannot be reliably concluded.29 
Functional studies suggested that urothelial β-adrenoceptors induce the release of a 
urothelium-derived factor which inhibits the β-adrenoceptor agonist-induced relaxation 
of the human detrusor smooth muscle.29 
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Thus, the capacity of mirabegron to influence the release of neurotrophins by 
urothelial cells may be substantial less than that of the antimuscarinic drugs, which 
might explain the lack of effect of mirabegron on the urinary levels of NGF and BDNF 
found in the present study. Interestingly, these findings may agree with the recent 
observation by Igawa and coworkers that mirabegron predominantly affects the A 
population of bladder sensory afferents, which are known to be little sensitive to 
neurotrophins.30 Nonetheless, it must be clear that, whatever the causes for the minor 
effect of mirabegron on urinary neurotrophins’ levels, it does not impair the clinical 
efficacy of the drug. Our patients observed a remarkable symptomatic benefit and a 
relevant improvement in quality of life. 
This study has some obvious limitations. Sample size was small, restricted to 
one center and no placebo arm was considered. 
 
 
CONCLUSIONS 
In contrast with other information about antimuscarinic agents, mirabegron 
seems not to produce significant changes in urinary levels of neurotrophins. However, 
this study confirms that it can cause marked symptomatic improvement. These data 
reduces NGF and BDNF utility in monitoring response to mirabegron in OAB. 
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TABLES AND FIGURES 
Table 1 
Table 1. Mean urinary NGF/Cr and BDNF/Cr ratios in female OAB patients and controls. NGF/Cr and 
BDNF/Cr were significantly higher in patients with OAB than in healthy women (p <0.05). 
 
Table 2 
Table 2.  Mean urinary NGF/Cr and BDNF/Cr ratios, KHQ and PPBC scores in OAB patients at baseline, 
after 4 weeks and after 12 weeks of treatment with mirabegron 50mg, once daily. No significant changes 
 Controls 
 (n=15) 
OAB patients 
 (n=22) 
p 
NGF/Cr pg/mg 2,4 ± 0.5 3.3 ± 0.6 <0,01 
BDNF/Cr pg/mg 2.6 ± 0.4 2.9 ± 0.5 0,028 
 
Baseline 
(n=22) 
4 weeks 
(n=21) 
12 weeks 
(n=20) 
NGF/Cr pg/mg 3.3 ± 0.6  3.2 ± 0.5 3.0 ± 0.8 
BDNF/Cr pg/mg 2.9 ± 0.5 2.7 ± 0.6 2.7 ± 0.5 
KHQ     
Part 1 
General Health Perception 
Incontinence Impact 
0 – 100% 
58 ± 18  
75 ± 21 
56 ± 13 
48 ± 27 * 
55 ± 19 
49 ± 31 * 
Part 2 
Role Limitations 
Physical Limitations 
Social Limitations 
Personal Relationships 
Emotions 
Sleep/Energy 
Severity Measures 
0 – 100% 
71 ± 17 
66 ± 24 
24 ± 23 
13 ± 26 
43 ± 21 
49 ± 27 
42 ± 23 
38 ± 32 * 
40 ± 30 * 
7 ± 15 * 
8 ± 20 
15 ± 20 * 
17 ± 21* 
22 ± 21 * 
32 ± 30 * 
27 ± 27 * 
7 ± 21 * 
12 ± 24 
9 ± 18 * 
18 ± 18 * 
24 ± 21 * 
Part 3 
Frequency 
Nocturia 
Urgency 
Urgency Incontinence 
Severity Scale: 
0 – Omitted 
1 – A little 
2 – Moderately 
3 – A lot 
2.3 ± 0.6 
1.4 ± 0.9 
2.5 ± 0.5 
2.1 ± 0.8 
1.9 ± 0.8 * 
0.3 ± 0.6 * 
1.5 ± 0.6 * 
0.8 ± 1.0 * 
1.5 ± 0.7 * 
0.5 ± 0.7 * 
1.5 ± 0.7 * 
1.0 ± 1.2 * 
PPBC 
Severity Scale: 
1 – 6 
3.6 ± 0.9 2.4 ± 1.0 * 2.4 ± 1.4 * 
Data is expressed as the mean   standard deviation 
Higher KHQ subscale score indicates lower health-related quality of life 
Higher PPBC score indicates more severe bladder problems 
* a p<0.05 is statistically significant when compared to baseline 
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occurred in NGF/Cr and BDNF/Cr ratios during treatment, despite a statistical significant decrease in the 
mean KHQ and PPBC scores. 
 
Figure 1 
 
Figure 1. Mean urinary NGF/Cr and BDNF/Cr ratios (tick marks) in OAB patients at baseline (n=22), after 
4 weeks (n=21) and after 12 weeks (n=20) of treatment with mirabegron 50mg, once daily. No significant 
changes occurred in NGF/Cr and BDNF/Cr ratios during treatment. Statistical significance was considered 
at p<0.05. 
 
0 
1 
2 
3 
4 
5 
baseline 4 weeks 12 weeks 
L
o
g 
(N
eu
ro
tr
o
p
h
in
/C
re
at
in
in
e)
 
NGF BDNF 
  
 
 
 
 
 
 
 
 
ANEXO(s) 
 
 
   
Normas de publicação na  revista: 
The Journal of Urology® 
 
Information for Authors
The Journal of Urology contains 4 sections: Adult Urology, Pediatric
Urology, Investigative Urology and Urological Survey. Rapid Communica-
tions are welcomed. The Adult and Pediatric Urology Sections
(original articles) usually do not publish laboratory animal studies. The
Investigative Urology Section (research articles) does not publish
clinically oriented articles, and does not require prior approval for Review
Articles. Unsolicited material is not accepted for Urological Survey.
All communications concerning editorial matters should be sent to:
The Journal of Urology
Publications Department
American Urological Association
1000 Corporate Boulevard
Linthicum, MD 21090
Telephone (410) 689-3922, FAX (410) 689-3906
e-mail: publications@auanet.org
MANUSCRIPT SUBMISSION. Authors must submit their manu-
scripts through the Web-based tracking system at https://www.editorial
manager.com/ju. The site contains instructions and advice on how to use the
system, guidance on the creation/scanning and saving of electronic art, and
supporting documentation. In addition to allowing authors to submit manu-
scripts on the Web, the site allows authors to follow the progression of their
manuscript through the peer review process. Authors are asked NOT to mail
hard copies of themanuscript to the editorial office. Theymay, however,mail to
the editorial office any material that cannot be submitted electronically.
For potentially acceptable manuscripts, the period between receipt
of all reviews andwhen an editorial decision is made is usually longer.
AUTHOR’SRESPONSIBILITY.Manuscriptsmust be accompanied by a
cover letter, an AUADisclosure Form and anAuthor Submission Requirement
Form (see last page) signed by all authors. The letter should include the com-
plete address, telephone number, FAX number and e-mail address of the des-
ignated corresponding author as well as the names of potential reviewers. The
corresponding author is responsible for indicating the source of extrainstitu-
tional funding, in particular that provided by commercial sources, internal
review board approval of study, accuracy of the references and all statements
made in their work, including changes made by the copy editor.
Manuscripts submitted without all signatures on all statements
will be returned to the authors immediately. Electronic signatures
are acceptable.
Authors are expected to submit complete and correct manuscripts. Due to
the large number of high quality articles being submitted and to avoid sig-
nificant delay in publication, the Editors find it necessary to insist that the
length of manuscripts, and number of references and illustrations conform
to the requirements indicated herein. No paper will be reviewed until these
requirements are met. Published manuscripts become the sole property of
The Journal of Urology and copyright will be taken out in the name of the
American Urological Association Education and Research, Inc.
All accepted NIH funded articles must be directly deposited to
PubMed Central by the authors of the article for public access 12
months after the publication date.
PAGE PROOFS AND CORRECTIONS. The corresponding author
will receive electronic page proofs to check the typeset article before pub-
lication. Portable document format (PDF) files of the typeset pages and
support documents (eg, reprint order form) will be sent to the corresponding
author by e-mail. Complete instructions will be provided with the e-mail for
downloading and printing the files and for faxing the corrected page proofs
to the editorial office.
It is the author’s responsibility to ensure that there are no errors in the
proofs.Changes thathavebeenmadetoconformto journal stylewill standif they
donot alter the author’smeaning.Only themost critical changes to the accuracy
of the content will be made. Changes that are stylistic or are a reworking of
previously acceptedmaterial will be disallowed. The editorial office reserves the
right to disallowextensivealterations.Authorsmaybecharged foralterations to
the proofs beyond those required to correct errors or to answer queries. Proofs
must be checked carefully and corrections faxedwithin 24 to 48 hours of receipt,
as requested in the cover letter accompanying the page proofs.
Rapid Review Manuscripts that contain important and timely infor-
mation will be reviewed by 2 consultants and the editors within 72 hours of
receipt, and authors will be notified of the disposition immediately thereafter.
The authors must indicate in their submittal letter why they believe
their manuscript warrants rapid review. A $250 processing fee should
be forwarded with the manuscript at the time of submission. Checks should
be made payable to the American Urological Association. If the editors
decide that the paper does not warrant rapid review, the fee will be returned
to the authors, and they may elect to have the manuscript continue through
the standard review process. Payment for rapid review guarantees only an
expedited review and not acceptance.
Original and Research Articles should be arranged as follows: Title
Page, Abstract, Introduction, Materials and Methods, Results, Discussion,
Conclusions, References, Tables, Legends. The title page should contain a
concise, descriptive title, the names and affiliations of all authors, and a brief
descriptive runninghead not to exceed 50 characters. One to five key words
should be typed at the bottom of the title page. These words should be identical
to the medical subject headings (MeSH) that appear in the Index Medicus of
the National Library of Medicine. The abstract should not exceed 250 words
(abbreviations are not to be substituted for whole words) and must conform to
the following style: Purpose, Materials and Methods, Results and Conclusions.
References should not exceed 30 readily available citations for all articles
(except Review Articles). Self-citations should be kept to a minimum. Refer-
ences should be cited by superscript numbers as they appear in the text, and
they should not be alphabetized. References should include the names and
initials of the first 3 authors, the complete title, the abbreviated journal name
according to the Index Medicus of the National Library of Medicine, the
volume, the beginning page number and the year. References to book chapters
should include names and initials of the first 3 chapter authors, chapter title,
book title and edition, names and initials of the first 3 book editors, city of
publisher, publisher, volume number, chapter number, page range and year.
In addition to the above, references to electronic publications should include
type of medium, availability statement and date of accession. The statistical
methods should be indicated and referenced. Enough information should be
presented to allow an independent critical assessment of the data.
Digital illustrations and tables should be kept to a necessary minimum
and their information should not be duplicated in the text. No more than 10
illustrations should accompany the manuscript for clinical articles. Magnifica-
tions for photomicrographs should be supplied and graphs should be labeled
clearly. Reference to illustrations, numbered with Arabic numerals, must be
provided in the text. Blurry or unrecognizable illustrations are not acceptable.
Visit http://www.elsevier.com/author-schemas/artwork-and-media-instructions
for detailed instructions for digital art. The use of color is encouraged at no
charge to the authors.
Tables should be numbered and referred to in the text. In general, they
should present summarized rather than individual raw data. Due to page
constraints caused by the large number of high quality manuscripts being
submitted to The Journal of Urology, the editors find it necessary to offer
publishing alternatives. Therefore, authors may be requested to post tables
and illustrations as supplementary material on The Journal website at no
charge or print tables and illustrations in the article at a per page rate of $236.
Letters to the Editor should be useful to urological practitioners. The
length should not exceed 500 words. Only Letters concerning articles pub-
lished in the Journal within the last year are considered.
Review Articles (comprehensive only) should not be submitted without
prior approval. Queries for these articles should be accompanied by a detailed
outline of the proposed article, an abstract not to exceed 750 words and an
estimate of the length of the manuscript to be submitted. The format is the
same as that of an Original Article.
Systematic reviews do not require prior approval for submission, and are
limited to 2500 words and 30 references.
Special Articles are scientific reports of original clinical research and
state-of-the-art topics, and are designated as such by the Editors. The
format is the same as that of an Original Article.
New Technology and Techniques feature high quality manuscripts
that describe the innovative clinical application of new technology or techni-
ques in all disciplines of urology, and are designated as such by the Editors.
Addressing diagnosis or management of urological conditions, this feature
covers the categories of 1) cutting-edge technology, 2) novel/modified techni-
ques and 3) outcomes data derived from use of 1 and/or 2. The format is the
same as that of an Original Article, although fewer words are preferred to
allow more space for illustrations.
Opposing Views are submitted by invitation only.
Video Clipsmay be submitted for posting on The Journal web site. They
are subject to peer review. Video files must be compressed to the smallest
possible size that still allows for high resolution and quality presentation. The
size of each clip should not exceed 10MB. File size limitation is intended to
ensure that end-users are able to download and view files in a reasonable time
frame. If files exceed the specified size limitation, they will not be posted to
the web site and returned to the author for resubmission. For complete
instructions e-mail: publications@auanet.org.
1898 j www.jurology.com
  
 
 
 
 
 
 
 
 
APÊNDICE(s) 
 
 
 
 Comprovativo de aprovação pela  
Comissão de Ética para a Saúde 
 



